PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib

VALUE IN HEALTH(2022)

引用 0|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要